CMV neutralizing antigen binding proteins
US9868777B2 · kind B2 · utility
3Cited by
0References
10Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 9, 2014 |
| Grant date | Jan 16, 2018 |
| Priority date | — |
| Expiry date | Jun 9, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q1/70
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention is directed to antigen binding proteins including, but not limited to, monoclonal antibodies and antigen binding fragments thereof, that specifically bind to and preferably neutralize human cytomegalovirus (CMV). Also encompassed by the invention are antigen binding proteins that have been humanized. The antigen binding proteins of the invention are useful as a therapeutic agent for treating and/or preventing CMV infections in a patient in need thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.